Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2

Objective In the PALOMA-2 trial, palbociclib in combination with letrozole prolonged progression-free survival (PFS) and exhibited an acceptable safety profile in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ABC). This post hoc analysis of PALOMA-2 evaluated the efficacy and safety of palbociclib plus letrozole in patients with preexisting conditions grouped by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC). Methods Postmenopausal patients without prior treatment for ABC were randomized 2:1 to receive palbociclib (125 mg/d on a 3 weeks on/1 week off schedule) plus letrozole (2.5 mg/d, continuous) or placebo plus letrozole. Patients were grouped by the following MedDRA SOC preexisting conditions: gastrointestinal, musculoskeletal, metabolic, and vascular/cardiac. Median PFS was estimated by the Kaplan-Meier method, and treatment emergent adverse events (AEs) were compared between treatment arms within each preexisting condition subgroup. Results At baseline, 276 (41.4 %) patients had preexisting gastrointestinal disorders, 390 (58.6 %) had musculoskeletal disorders, 259 (38.9 %) had metabolic disorders, and 382 (57.4 %) had vascular/cardiac disorders. Baseline characteristics were similar between subgroups and between each arm within subgroups. Regardless of baseline preexisting condition, palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole. Treatment-emergent AEs associated with palbociclib plus letrozole and dose modifications due to AEs were similar across preexisting condition subgroups. Conclusion This post hoc analysis of PALOMA-2 demonstrated a favorable effect of palbociclib on PFS and a safety profile consistent with previous observations, regardless of underlying preexisting condition. Pfizer Inc (NCT01740427).

• Publication year

  2021

• Venue

  Breast

• Publication date

  2021-07-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.breast.2021.07.017PMID 34388698PMCID 8361185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up

  2021cited by this paper
• Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors

  2019cited by this paper
• Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

  2019cited by this paper
• Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.

  2018cited by this paper
• Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis

  2017cited by this paper
• Palbociclib and Letrozole in Advanced Breast Cancer.

  2016cited by this paper
• The impact of comorbidity on cancer and its treatment

  2016cited by this paper
• Comorbid Diseases Interact with Breast Cancer to Affect Mortality in the First Year after Diagnosis—A Danish Nationwide Matched Cohort Study

  2013cited by this paper
• The impact of comorbidity on cancer survival: a review

  2013cited by this paper
• An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer

  2011cited by this paper
• Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study.

  2005cited by this paper
• Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.

  2005cited by this paper

• Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study.

  2026cites this paper
• Palbociclib-Induced Interstitial Lung Disease in Metastatic Breast Cancer: A Case Report and Clinical Considerations

  2025cites this paper
• Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors

  2025cites this paper
• Tolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen receptor-positive/HER2-negative breast cancer: results of a prospective observational study

  2025cites this paper
• Long term efficacy of adjuvant chemotherapy in elderly patients with early stage breast cancer assessed through SEER database analysis

  2025cites this paper
• Drug treatment of breast cancer brain metastases: progress and challenges

  2025cites this paper
• Hepatic Adverse Events with CDK4/6 Inhibitors: A systematic review combining meta-analysis and FAERS Database.

  2025cites this paper
• Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors

  2025cites this paper
• The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world study

  2024influential citation
• Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer

  2024cites this paper
• Research Progress in First-Line Treatment for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

  2024cites this paper
• Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.

  2024cites this paper
• CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis

  2024cites this paper
• Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer

  2024cites this paper
• Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study

  2024cites this paper
• Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness

  2024cites this paper
• Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer.

  2024cites this paper
• Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study

  2024cites this paper
• Palbociclib: randomisierte Studien und Real-World-Evidenz als Grundlage für die Therapieplanung beim metastasierten Mammakarzinom

  2024cites this paper
• Retrospective registry of patients with locally advanced/metastatic HR+/HER2− breast cancer treated in clinical practice in Andalusia

  2023cites this paper
• Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape

  2023cites this paper
• Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors

  2023cites this paper
• Real‐world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database

  2023cites this paper
• Palbociclib: efficacy and safety in older patients

  2023cites this paper
• Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.

  2023cites this paper
• Reporting of older subgroups in registration breast cancer trials 2012–2021

  2023cites this paper
• The Renaissance of Cyclin Dependent Kinase Inhibitors

  2022cites this paper
• The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?

  2022cites this paper